Methods of oral immunotherapy
The present disclosure relates to improved oral immunotherapy methods for treating food allergies, and particularly peanut allergy. Biomarkers, such as a level of peanut-specific IgE and/or peanut-specific IgG4s are used by the methods described herein. Such methods include a method of treating a subject for a peanut allergy, methods of assessing the suitability of a treatment for a peanut allergy, a method of evaluating a symptom in a subject during the course of treatment of a peanut allergy, a method of monitoring treatment for a peanut allergy in a subject, a method of reducing the risk or incidence of an adverse event in a subject receiving treatment for a peanut allergy, a method of adjusting a dose of an allergenic peanut composition, and a method of assessing a likelihood of an allergic reaction that requires administration of epinephrine to a subject receiving treatment for a peanut allergy.
1. A method of reducing the risk or incidence of an adverse event in a subject receiving treatment for a peanut allergy, comprising:
measuring a level of peanut-specific IgEs and a level of peanut-specific IgG4s in the subject;
measuring a ratio of the peanut-specific IgEs to the peanut-specific IgG4s; and
administering a reduced dose, delaying the administration of a dose, or delaying administration of an increase of a dose of an allergenic peanut composition if the level of peanut-specific IgEs is above a predetermined threshold, and if the ratio of the peanut-specific IgEs to the peanut-specific IgG4s increases during treatment compared to an earlier measurement during treatment or within 7 days of the start of treatment.
2. The method of claim 1 , wherein the treatment is oral immunotherapy.
3. The method of claim 1 , wherein the predetermined threshold of the peanut-specific IgEs is 100 KU/L.
4. The method of claim 1 , wherein the adverse event is an allergic reaction.
5. The method of claim 1 , comprising administering the dose to the subject.
6. A method of monitoring treatment for a peanut allergy in a subject, comprising:
measuring a level of peanut-specific IgEs and a level of peanut-specific IgG4s in a sample of the subject during the course of treatment; and
measuring a ratio of the peanut-specific IgE to the peanut-specific IgG4, wherein the subject undergoes heightened monitoring for an allergenic reaction if the level of peanut-specific IgEs is above a predetermined threshold, and if the ratio of the peanut-specific IgEs to the peanut-specific IgG4s increases during the course treatment compared to an earlier measurement during treatment or within 7 days of the start of treatment, and wherein the monitoring is heightened compared to a subject having a level of peanut-specific IgEs at or below the predetermined threshold.
7. The method of claim 1 , wherein the level of peanut-specific IgEs, peanut-specific IgG4s, or both, is measured by a quantitative immunoassay or fluorescence enzyme immunoassay auto-analyzer.
8. The method of claim 6 , wherein the predetermined threshold of the peanut-specific IgEs is 100 kU/L.